Filamentous influenza A virus infection predisposes mice to fatal septicemia following superinfection with Streptococcus pneumoniae serotype 3.
Previous studies have demonstrated that animals exposed to Streptococcus pneumoniae while recovering from influenza A virus infection exhibit exacerbated disease symptoms. However, many of the current animal models exploring dual viral and bacterial synergistic exacerbations of respiratory disease have utilized mouse-adapted influenza virus and strains of Streptococcus pneumoniae that in themselves are highly lethal to mice. Here we describe a mouse model of bacterial superinfection in which a mild, self-limiting influenza virus infection is followed by mild, self-limiting superinfection with S. pneumoniae serotype 3. S. pneumoniae superinfection results in rapid dissemination of the bacterium from the respiratory tract and systemic spread to all major organs of the mice, resulting in fatal septicemia. This phenomenon in mice was observed in superinfected animals undergoing an active viral infection as well as in mice that had completely cleared the virus 7 to 8 days prior to superinfection. Neutrophils were the predominant cellular inflammatory infiltrate in the lungs of superinfected mice compared to singly infected animals. Among other cytokines and chemokines, the neutrophil activator granulocyte colony-stimulating factor (G-CSF) was found to be significantly overexpressed in the spleens, lungs, and brains of superinfected animals. High G-CSF protein levels were observed in sera and lung lavage fluid from superinfected animals, suggesting that G-CSF is a major contributor to synergistic exacerbation of disease leading to fatal septicemia.
Speshock
Janice L
JL
Department of Biomedical Sciences and Pathobiology, Centers for Molecular Medicine and Infectious Diseases, Virginia Tech, 1410 Prices Fork Road (0342), Blacksburg, VA 24061, USA.
Doyon-Reale
Nicole
N
Rabah
R
R
Neely
Melody N
MN
Roberts
Paul C
PC
D000818:Animals; D004195:Disease Models, Animal; D004198:Disease Susceptibility; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D006801:Humans; D009980:Influenza A virus / Q000276:immunology*; D007251:Influenza, Human / Q000150:complications* / Q000276:immunology; D051379:Mice; D008807:Mice, Inbred BALB C; D009976:Orthomyxoviridae Infections / Q000150:complications*; D011008:Pneumococcal Infections / Q000209:etiology / Q000276:immunology* / Q000382:microbiology / Q000401:mortality*; D018805:Sepsis / Q000209:etiology / Q000401:mortality*; D013296:Streptococcus pneumoniae / Q000276:immunology; D015163:Superinfection / Q000382:microbiology / Q000473:pathology
D016178:Granulocyte-Macrophage Colony-Stimulating Factor